BioNTech SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ugur Sahin
- Full Time Employees
- 7,807
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- An der Goldgrube 12 Mainz RP Germany 55131
- IPO Date
- Oct 10, 2019
- CIK
- 0001776985
- Website
- biontech.com
- Similar Companies
- Business
- BioNTech SE (BNTX) is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. The company offers a broad portfolio of products and services, including mRNA-based therapeutics and vaccines such as Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer; individualized neoantigen-specific immunotherapies under the BioNTech's FixVac and iNeST platforms; antibody-drug conjugates; small molecule immunomodulators; and cell therapies targeting solid tumors and hematological malignancies; as well as oncology pipeline candidates like BNT327 (a PD-L1/VEGF bispecific antibody) and BNT116 (a next-generation FixVac for lung cancer). BioNTech operates primarily in the biopharmaceutical industry, serving global patient populations through clinical trials, regulatory approvals, and commercial distribution in over 30 countries across North America, Europe, Asia-Pacific, and emerging markets. Founded in 2008 and headquartered in Mainz, Germany, the company maintains subsidiaries worldwide, including in the United States, the United Kingdom, and China, with no parent company. Recent developments include the European Medicines Agency's approval in 2024 for BNT116 as the first mRNA-based lung cancer therapeutic; a multi-billion-dollar expansion of its manufacturing facilities in Rwanda and Australia announced in early 2025 to enhance global vaccine production capacity; deepened strategic alliances with Pfizer for next-generation COVID-19 vaccines and with Genentech for bispecific antibody development; and a $760 million funding round in late 2024 to advance its oncology pipeline amid robust Phase 3 trial progress.
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.
Bank of New York Mellon Corp Trims Stock Position in BioNTech SE Sponsored ADR $BNTX
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech Q2 Earnings Call Highlights
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
BioNTech says Sobi's Oelkers will replace Sahin as CEO
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baader Bank Aktiengesellschaft
Amova Asset Management Americas Inc. Invests $6.91 Million in BioNTech SE Sponsored ADR $BNTX
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
BioNTech held buyer talks over four German sites set to close, Handelsblatt reports
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO